362 related articles for article (PubMed ID: 34072318)
1. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.
Ridyard KE; Overhage J
Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34072318
[TBL] [Abstract][Full Text] [Related]
2. The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds.
Duplantier AJ; van Hoek ML
Front Immunol; 2013; 4():143. PubMed ID: 23840194
[TBL] [Abstract][Full Text] [Related]
3. Design and characterization of a new hybrid peptide from LL-37 and BMAP-27.
Al Tall Y; Abualhaijaa A; Alsaggar M; Almaaytah A; Masadeh M; Alzoubi KH
Infect Drug Resist; 2019; 12():1035-1045. PubMed ID: 31118709
[No Abstract] [Full Text] [Related]
4. The evaluation of the synergistic antimicrobial and antibiofilm activity of AamAP1-Lysine with conventional antibiotics against representative resistant strains of both Gram-positive and Gram-negative bacteria.
Almaaytah A; Abualhaijaa A; Alqudah O
Infect Drug Resist; 2019; 12():1371-1380. PubMed ID: 31213855
[No Abstract] [Full Text] [Related]
5. Antibacterial Properties and Efficacy of a Novel SPLUNC1-Derived Antimicrobial Peptide, α4-Short, in a Murine Model of Respiratory Infection.
Jiang S; Deslouches B; Chen C; Di ME; Di YP
mBio; 2019 Apr; 10(2):. PubMed ID: 30967458
[TBL] [Abstract][Full Text] [Related]
6. Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?
Zharkova MS; Orlov DS; Golubeva OY; Chakchir OB; Eliseev IE; Grinchuk TM; Shamova OV
Front Cell Infect Microbiol; 2019; 9():128. PubMed ID: 31114762
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Activities of Nisin and Nisin Derivatives Alone and In Combination with Antibiotics against Staphylococcus Biofilms.
Field D; O' Connor R; Cotter PD; Ross RP; Hill C
Front Microbiol; 2016; 7():508. PubMed ID: 27148197
[TBL] [Abstract][Full Text] [Related]
8. Using anti-biofilm peptides to treat antibiotic-resistant bacterial infections.
de la Fuente-Núñez C; Hancock RE
Postdoc J; 2015 Feb; 3(2):1-8. PubMed ID: 27563687
[TBL] [Abstract][Full Text] [Related]
9. Short, Synthetic Cationic Peptides Have Antibacterial Activity against Mycobacterium smegmatis by Forming Pores in Membrane and Synergizing with Antibiotics.
Gupta K; Singh S; van Hoek ML
Antibiotics (Basel); 2015 Aug; 4(3):358-78. PubMed ID: 27025629
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of LFchimera and antibiotic against planktonic and biofilm form of Aggregatibacter actinomycetemcomitans.
Lachica MRCT; Anutrakunchai C; Prajaneh S; Nazmi K; Bolscher JGM; Taweechaisupapong S
PLoS One; 2019; 14(7):e0217205. PubMed ID: 31329599
[TBL] [Abstract][Full Text] [Related]
11. HAZ, a novel peptide with broad-spectrum antibacterial activity.
Alsaggar M; Al-Hazabreh M; Al Tall Y; Al-Tarawneh A; Darweesh RS; Masadeh M
Saudi Pharm J; 2022 Nov; 30(11):1652-1658. PubMed ID: 36465844
[TBL] [Abstract][Full Text] [Related]
12. Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance.
Ferreira M; Ogren M; Dias JNR; Silva M; Gil S; Tavares L; Aires-da-Silva F; Gaspar MM; Aguiar SI
Molecules; 2021 Apr; 26(7):. PubMed ID: 33918529
[TBL] [Abstract][Full Text] [Related]
13. The design of a cell-selective fowlicidin-1-derived peptide with both antimicrobial and anti-inflammatory activities.
Rajasekaran G; Kumar SD; Yang S; Shin SY
Eur J Med Chem; 2019 Nov; 182():111623. PubMed ID: 31473417
[TBL] [Abstract][Full Text] [Related]
14. WLBU2 Antimicrobial Peptide as a Potential Therapeutic for Treatment of Resistant Bacterial.
Elsalem L; Khasawneh A; Al Sheboul S
Turk J Pharm Sci; 2022 Feb; 19(1):110-116. PubMed ID: 35227034
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel antibacterial agent for the infected wound treatment: all-hydrocarbon stapling optimization of LL-37.
Zhang Y; Zheng M; Wang Z; Liu Z; Chen S; Li X; Shi Y; Hu H
Theranostics; 2024; 14(3):1181-1194. PubMed ID: 38323312
[No Abstract] [Full Text] [Related]
16. Evaluation of the Antimicrobial Peptide, RP557, for the Broad-Spectrum Treatment of Wound Pathogens and Biofilm.
Woodburn KW; Jaynes JM; Clemens LE
Front Microbiol; 2019; 10():1688. PubMed ID: 31396193
[TBL] [Abstract][Full Text] [Related]
17. Interaction of the core fragments of the LL-37 host defense peptide with actin.
Sol A; Wang G; Blotnick E; Golla R; Bachrach G; Muhlrad A
RSC Adv; 2015; 5(13):9361-9367. PubMed ID: 26726303
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial and anti-inflammatory activities of chemokine CXCL14-derived antimicrobial peptide and its analogs.
Rajasekaran G; Dinesh Kumar S; Nam J; Jeon D; Kim Y; Lee CW; Park IS; Shin SY
Biochim Biophys Acta Biomembr; 2019 Jan; 1861(1):256-267. PubMed ID: 29959905
[TBL] [Abstract][Full Text] [Related]
19. The impact of N-glycosylation on the properties of the antimicrobial peptide LL-III.
Tortorella A; Leone L; Lombardi A; Pizzo E; Bosso A; Winter R; Petraccone L; Del Vecchio P; Oliva R
Sci Rep; 2023 Mar; 13(1):3733. PubMed ID: 36878924
[TBL] [Abstract][Full Text] [Related]
20. Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides.
Dosler S; Karaaslan E
Peptides; 2014 Dec; 62():32-7. PubMed ID: 25285879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
